header logo en

 

10 facts web


Safety, Tolerability, and Efficacy of

Pembrolizumab (MK-3475) in

Combination With Epacadostat

(INCB024360) 

 
 
 Last updated: January 30, 2017
 STATUS: Cohort closed for kidney cancer patients (pending confirmation) (ClinicalTrials.gov/NCT02178722)

WHO

is the trial for?

Patients with kidney cancer (Renal cell carcinoma, RCC) are only eligible for phase I of the trial. Patients have to meet the following criteria:

  • confirmed advanced renal cell carcinoma
  • at least one prior therapy, but
  • no prior therapy with anti-PD-1, anti-PD-L1, or anti- CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).

WHAT

is the key question that this trial is attempting to answer?

This phase-I study aims to evaluate the safety and tolerability of a new immune therapy combination for patients with kidney cancer.

This study will examine the effect of a treatment with the antibody pembrolizumab (MK-3475) in combination with the immunomodulating agent epacadostat (INCB024360) on tumours of participants with selected cancers such as renal cell carcinoma.

WHY

patients might want to participate?

This clinical trial offers patients an opportunity to access a new therapy that may be effective for kidney cancer. This trial will further support the research in kidney cancer and potentially help other patients with kidney cancer. The trial might or might not have benefit in your individual case. For more about the importance and benefits of joining clinical trials, please click here.

WHEN

will the trial be open?

Cohort closed for kidney cancer patients (pending confirmation) – 374 patients are currently expected to participate.

WHERE

is the trial available?

The trial will be available in 15 cancer centres in the USA.
For contact details, please click here:
 

STUDY

DESIGN

What does the study look like?

This study will be conducted in 2 phases. Patients with kidney cancer (renal cell carcinoma) are only eligible for phase I of the trial. The study will test different doses of epacadostat (INCB024360) in combination with pembrolizumab (MK-3475) in order to select a dose for further evaluation in phase-II.

  • pembrolizumab (Keytruda™) is a fully human monoclonal antibody targeting PD-1
  • epacadostat (INCB024360) is an immunomodulating agent 

HOW

do I get more information?

Patient organisations supporting kidney cancer patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organisations serving kidney cancer patients. If there are no such organisations in your country, please email us for more information: This email address is being protected from spambots. You need JavaScript enabled to view it.

CONNECT

with other patients on this trial

If you want to connect with other patients considering or participating in this trial, you can find them here: List of organisations worldwide.

SHARE

your experience 

If you are participating on this trial and want to share your experiences, please feel free to send us an e-mail to: This email address is being protected from spambots. You need JavaScript enabled to view it.
Note that your experience (with your name omitted) would be helpful for other patients and patient organisations.

RESULTS

of the study

No results are available at this time. Future results will be linked here.

Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.

Back to clinical trials overview: How can I find an IO clinical trial for my cancer?